ZUMA-7 Study Shows Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large B-Cell Lymphoma
John Theurer Cancer Center Investigators Participate in International Study Showing 60% EFS Improvement Over Standard Regimen
Results of the multicenter ZUMA-7 study demonstrate that using CAR T-Cell therapy as the second line of treatment for large B-cell lymphoma (LBCL) that has returned or continued to grow after initial treatment was more effective than the standard second-line regimen of care for improving event-free survival.
With a median follow-up of two years, the study showed that patients with LBCL who received a one-time infusion of axicabtagene ciloleucel (Yescarta®) experienced a 60% improvement in EFS (defined as disease progression, needing to start a new lymphoma treatment, or death from any cause) compared with patients who received standard care with chemotherapy and autologous stem cell transplantation. Patients in the CAR T-Cell therapy group also experienced a better overall response rate.
Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, a part of Georgetown Lombardi Comprehensive Cancer Center, participated in the international study.
"This is a very exciting paradigm shift for the treatment of large B-cell lymphoma," explained hematologist-oncologist Lori Leslie, M.D., who led JTCC's participation in the ZUMA-7 study. "A 60% improvement in event-free survival is more dramatic than one would anticipate and suggests that early relapsers and some patients at high risk of relapse after initial treatment may benefit from proceeding directly to CAR T-Cell therapy."
About 40% of patients with LBCL require a second regimen of treatment. Axicabtagene ciloleucel is currently approved by the U.S. Food and Drug Administration for the treatment of large B-cell lymphoma that relapses or continues to grow after at least two prior regimens of therapy.
The study is continuing with additional follow-up to assess the effect of the treatments on overall survival and other key endpoints.
Learn More about cancer care breakthroughs at Hackensack University Medical Center.